… ERK inhibitors in pre-clinical models and in human clinical trials for KRAS mutant lung cancer
… their benefit is limited for patients with KRAS mutant NSCLC due to the lack of predictive …

… of the RAF, MEK or ERK kinase inhibitors developed thus far have been approved for the
treatment of KRAS mutant tumors. Only the MEK inhibitor selumetinib has been approved for …

… f, Clonogenic assay of H23 cells treated with trametinib, ERK inhibitor SCH772984, or a
combination as indicated (n = 3). g, Immunoblot of KRAS-mutant lung cancer cells treated with …

… Remarkably, CRAF, but not BRAF, was essential to mediate signalling to MEK and ERK
kinases in KRAS-G12V-driven NSCLCs in mice, and elimination of CRAF, but not BRAF, from …

… to maintain KRAS-mutant lung cancer cell viability, we first assessed a panel of lung cancer
cell … is expressed in most lung cancer cells at varying levels. We then depleted MAP3K19 in …

… Combined inhibition of RAF and STAT3 blocked MEK/ERK signaling pathway To determine
whether the synergistic effects on KRAS mutant lung cancer cells were associated with …

… KRAS-mutant lung cancer cell lines further demonstrated that long-term MEK inhibition induces
rebound activation of ERK … observed in many of the KRAS-mutant lung cancer cell lines. …

… in KRAS-mutant lung adenocarcinoma. We … KRAS mutation both in the human lung
adenocarcinoma cell lines and tissues. PD-L1 was up-regulated by KRAS mutation through p-ERK …

… Given the promising response of H157 cells to the combined inhibition of JAK2/STAT3
and MEK/ERK, we further investigated the effects of the combined treatment of AZD6244 and …

… following treatment with MEK inhibitor, which relieves … KRAS mutant lung cancer cell
lines, knockdown of FGFR1 or addition of FGFR inhibitor negated feedback activation of ERK …